SCHEMBL3354571

SCHEMBL3354571

Cc1cc(CC(OC(=O)N2CCC(n3cc(-c4ccccc4)[nH]c3=O)CC2)C(=O)N2CCC(N3CCN(C)CC3)CC2)cc2cn[nH]c12

nearest known ligand 0.89

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 15/20 0.89
CYP3A4 P08684 1/20 0.53
CALCA P06881 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354566 1.00 CALCRL (0.89) CALCRLCYP3A4CALCA
SCHEMBL3358046 0.98 CALCRL (0.88) CALCRLCYP3A4CALCA
SCHEMBL3358053 0.98 CALCRL (0.88) CALCRLCYP3A4CALCA
SCHEMBL3354196 0.94 CALCRL (0.83) CALCRLCYP3A4
SCHEMBL13204027 0.94 CALCRL (0.83) CALCRLCYP3A4
SCHEMBL2981927 0.94 CALCRL (1.00) CALCRLCALCA
SCHEMBL2971778 0.94 CALCRL (1.00) CALCRLCALCA
SCHEMBL3355393 0.94 CALCRL (0.78) CALCRLCYP3A4CALCA
SCHEMBL3355402 0.94 CALCRL (0.78) CALCRLCYP3A4CALCA
SCHEMBL3353709 0.92 CALCRL (0.77) CALCRLCYP3A4CALCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7696195-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-13 US disclosed
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA CALCRL 1/4885CYP3A4 1001/4885CALCA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.